Groundbreaking Study Findings on SBK007 Presented at EAACI Congress 2026

From 12 to 15 June 2026, the preclinical study findings of SBK007, a novel next‑generation anti‑allergic agent independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd., were presented and discussed at the European Academy of Allergy and Clinical Immunology Congress 2026 (EAACI Congress 2026). The presentation was titled SBK007: A Novel Oral H1 Antihistamine with Rapid Onset (30min): Preclinical Pharmacodynamics in Acute Urticaria.

EAACI 2026: A Leading Global Conference in Allergy and Immunology

The European Academy of Allergology and Clinical Immunology (EAACI) stands as the leading professional organization globally in the fields of allergy and clinical immunology. Its annual congress represents the most prestigious and academically influential international event in this domain. Under the theme of Vision Zero: A Future Free from Allergy and Asthma Burden, EAACI Congress 2026 was jointly organized by Prof. María José Torres, current President of EAACI, and Prof. André Moreira, Chair of the Congress. The event attracted over 20,000 experts from more than 100 countries worldwide, serving as a premier platform for exchanging cutting-edge advancements in allergy diagnosis, treatment, and pharmaceutical development.

SBK007: A Fast-Acting Novel Antihistamine Addressing Critical Unmet Needs in Acute Urticaria

SBK007 is an orally administered H1 antihistamine independently developed by Shibeikang . Preclinical studies indicate that it exhibits rapid onset of action, achieving therapeutic effects within just 30 minutes. Its efficacy demonstrates clear dose-dependency and significantly outperforms existing comparator drugs. Consequently, SBK007 is well-positioned to meet the urgent need for immediate symptom control among patients suffering from acute urticaria, potentially offering a convenient and efficient oral therapeutic alternative—particularly for severe or emergency cases. The data presented at the Congress provide robust scientific justification for advancing SBK007 into subsequent phases of clinical development.